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Background & Aims: Hy´s Law, which states that hepatocellular drug-induced liver injury (DILI) with jaundice indicates a serious reaction, is widely used to determine risk for acute liver failure (ALF). We aimed to optimize the definition of Hy´s Law and to develop a model for predicting ALF in patients with DILI.
Methods:
We collected data from 771 patients with DILI (805 episodes) from the Spanish DILI registry in Spain, from April 1994 through August 2012. We analyzed data collected at DILI recognition and at the time of peak levels of alanine aminotransferase (ALT) and total bilirubin (TBL).
Results:
Of the 771 patients with DILI, 32 developed ALF. Hepatocellular injury, female sex, high levels of TBL, and a high ratio of aspartate aminotransferase (AST):ALT were independent risk factors for ALF. We compared 3 ways to use Hy's Law to predict which patients would develop ALF; all included TBL>2-fold the upper limit of normal (xULN) and either ALT>3xULN, an R value (ALT x ULN/ alkaline phosphatase x ULN) ≥5, or an nR value (ALT or AST, whichever produces the highest xULN/ alkaline phosphatase x ULN value) ≥5. At recognition of DILI, the R-and nRbased models identified patients who developed ALF with 67% and 63% specificity, respectively, whereas use of only ALT level identified them with 44% specificity.
However, level of ALT and the nR model each identified patients who developed ALF with 90% sensitivity, whereas the R criteria identified them with 83% sensitivity. An equal number of patients who did and did not develop ALF had alkaline phosphatase levels >2xULN. An algorithm based on AST>17.3 x ULN, TBL >6.6 x ULN, and AST:ALT >1.5 identified patients who developed ALF with 82% specificity and 80% sensitivity.
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Introduction
Drug-induced liver injury (DILI) is a challenge for clinicians, the pharmaceutical industry and regulatory agencies. 1 Furthermore, acute DILI has been reported to occur in 5% to 10% of patients hospitalized for jaundice, 2 and more often evolves to fulminant hepatic failure than other causes of acute hepatic injury in Western countries. 3, 4 Idiosyncratic hepatotoxicity was the presumptive cause in 13% to 15% of cases of acute liver failure in reports from the United States and Sweden, respectively. 3, 4 The spontaneous survival for patients with acute liver failure due to idiosyncratic drug reactions is usually poor with 60% to 80% mortality without liver transplantation. 5, 6 Hyman Zimmerman, the pioneer of modern hepatotoxicology, 7 in the late 1960s
observed that the combination of jaundice and drug-induced hepatocellular injury was associated with a 10% to 50% fatality rate from liver failure (before liver transplantations were performed), provided that other causes for increased bilirubin levels were excluded (hemolysis, Gilbert syndrome and a major component of cholestasis 
Patients and Methods
The study cohort encompassed all patients with idiosyncratic drug-induced liver injury 
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Results
Demographic and clinical presentation of DILI patients who did or did not develop ALF/OLT
Seven hundred and seventy-one patients, who presented 805 DILI episodes between April 1994 and August 2012, were included in the analysis. Thirty-two of these DILI patients (4%) developed ALF resulting in death (19, 59%), OLT (12, 38%) or recovery
(1, 3%). Additionally, 10 patients died within 6 months of DILI recognition due to nonliver related causes. The overall mean age was 54 years (range, 11-89 years) and 394 (51%) were men. The main causative drug group was antibiotics (36%), followed by nervous system (13%), musculoskeletal (12%), cardiovascular drugs (12%) and antineoplastic agents (8%). Jaundice was present in 66% and 52% of the episodes required hospitalization. The mean time between the first blood analysis after DILI initiation and death/liver transplantation in the ALF group was 26.6 days.
When comparing demographics and clinical presentation of the DILI patients (Table 1) we found a female preponderance in the ALF/OLT group ( 
Comparison of laboratory parameters in DILI episodes which did or did not progress to ALF/OLT
We evaluated TBL, ALT, AST, ALP levels and AST/ALT ratio at different time points:
DILI recognition (first labs), peak of ALT and peak of TBL (Supplementary Table 2 ).
At DILI recognition and peak of ALT median values of TBL, AST, ALT and AST/ALT were significantly higher in the ALF/OLT group compared to DILI patients with a favourable outcome (p<0.001). At peak of TBL, the median of TBL, AST and AST/ALT, but not ALT, were also significantly higher in the ALF/OLT group (p<0.001). There were no significant differences in ALP values between the two groups at any of the time points.
Logistic regression analysis of demographic, clinical and laboratory parameters associated with ALF/OLT
We then used a logistic regression model to determine which parameters were predictive with respect to ALF/OLT development at the different time points. We found that TBL and AST/ALT ratio at the three time points, hepatocellular injury at DILI recognition and TBL peak and female gender at DILI recognition and ALT peak were significant (Table 2) .
Detailed demographic, clinical and laboratory parameters corresponding to the 31 patients who developed ALF resulting in death or OLT are shown in Supplementary 
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Improving Hy´s Law definition for ALF prediction
In search of the best way to define Hy´s Law for predicting an ALF outcome we compared three sets of inclusion criteria, using either the standard TBL>2xULN and ALT>3xULN alone or with the inclusion of, R≥5 or nR≥5; (nR: ALT or AST, whichever highest xULN/ALP xULN). The rationale for assessing nR was based on the finding that AST level was found to be an important predictive value for ALF/OLT development at all time points. The performance of the three definitions was then compared at DILI recognition, peak of ALT and peak of TBL (Table 3) .
ALT criteria
Almost half of all the cases in our registry fulfilled the ALT criteria at all time points.
At ALT peak, 28 of the 336 cases fulfilling the criteria developed ALF resulting in person who will never go to ALF. Furthermore, the probability of having a negative test
for individuals who will develop ALF is 0.16 times or about one-sixth of that of those who never will develop ALF. Three ALF cases were not identified with the nR criteria.
Of these, one hepatocellular case did not fulfill TBL>2 xULN at enrollment and two cases had cholestatic/mixed type of injury. One was first seen very late (51 days after onset of symptoms) so the DILI peak was probably missed, while the other was a complex case with basal cholestasis of unknown cause in a co-infected HIV and HCV patient on antituberculosis treatment (Supplementary Table 1 ). The nR criteria were found to be most predictive at DILI recognition compared to the other time points (Table 3 ). The decrease in sensitivity at peak ALT and peak TBL with the R and the nR criteria paralleled the evolution of injury pattern, which tended to transition towards cholestatic/mixed as the condition progresses (Figure 1 ).
Effect of ALP >2 xULN on ALF development
Using the same time points, we also examined whether an ALP >2 xULN indicates cholestatic predominance and therefore decreases the risk of ALF/OLT. The percentage of patients with ALP >2 xULN was not significantly different between episodes which did or did not go on to develop ALF/OLT, suggesting that an ALP>2 xULN does not have a protective role in ALF development (Table 4) . Hence, ALP levels >2 xULN does not exclude Hy´s Law as it was observed in a quarter of the ALF cases, but was rarely 
Comparison of the four prognostic methods for ALF prediction at DILI recognition
We then determined the ROC areas (AUROC): 0.67 (ALT criteria), 0.74 (R criteria), 0.77 (nR criteria) and 0.80 (prognostic algorithm), Figure 3 . Furthermore, we compared the four methods using the McNemar test to determine statistical significant differences in sensitivity and specificity. Here we found differences in specificity: ALT vs R p<0.001, ALT vs nR p<0.001, ALT vs algorithm p<0.001, R vs nR p=0.004, R vs algorithm p<0.001, nR vs algorithm p<0.001, but not in sensitivity, which may be due to the small size of the ALF cohort.
Application of new Hy's Law definitions and a new ALF algorithm in an independent
Latin American DILI cohort 
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19 which 4 developed ALF/OLT. This translates to 80% sensitivity and 68% specificity.
We then applied the new ALF algorithm, which resulted in the prediction of 20 cases with increased risk of developing ALF/OLT, including 4 of the 5 cases that in fact had an ALF/OLT outcome. Hence, the ALF algorithm demonstrated 80% sensitivity and 82% specificity. These results are very similar to those obtained with the Spanish DILI Registry cohort, especially using the ALF algorithm.
Discussion
Prediction of severe outcome at DILI recognition remains a challenge in clinical practice. Prompt discontinuation of the offending drug is a crucial step in DILI management, but it is not enough by itself to prevent further damage and even a fulminant outcome in some cases. Assessment of DILI severity is based upon derangement in coagulation parameters and the development of encephalopathy. 13, 18 However, these are delayed features and at this time point liver parenchymal mass is extensively lost and liver function severely and irreversibly affected in most patients.
Acute liver failure related to idiosyncratic drug reactions is typically delayed, 19 encephalopathy ensuing up to 26 weeks after jaundice, which makes it particularly important from a clinical perspective to be able to predict who is at risk for ALF at the initial clinical assessment. Furthermore, identifying more precisely those at higher risk of ALF would potentially provoke more close observation, hospitalization or immediate referral to a transplant center. Alternatively immediate identification of higher risk might lead to alternative therapeutic interventions or selection for clinical trials of new treatments. Due to the lack of specific biomarkers to predict progression of liver necrosis at early stages of acute DILI, it is necessary to rely on commonly used liver tests for this purpose. In the present study we have used the prospective Spanish DILI M A N U S C R I P T was not associated with a worse DILI outcome. Of note, in the DILIN cohort the majority of the deaths were not liver related, which may account for the difference.
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Dyslipidemia was less frequent in ALF/OLT cases than in patients with a favorable outcome. The reasons for the "protective" effect of a history of dyslipidemia are unclear but could be related to the more frequent use of statins by the latter group (8.7% vs 3.2%). Statins exert several potentially beneficial effects on the liver in experimental models; enhancing nitric oxide production, targeting cholesterol at different levels in the mevalonate pathway and inhibiting drug-induced expression of genes involved in oxidative stress response, drug transport, DNA repair, cell cycle progression and cell death, thus protecting from ischemia/reperfusion, 24 , hepatotoxicity 25 and drug-induced acute liver failure. 26 Statins also improve aminotransferase levels 27 in patients with M A N U S C R I P T
21 hepatitis C and have an additive effect, when combined with nonselective beta blockers, in reducing portal pressure in patients with cirrhosis. 28 The finding of reduced dyslipidemia, and subsequent statin intake , in ALF/OLT patients is at this stage a novel observation, but requires further confirmatory studies.
Interestingly, the degree of aminotransferase elevation was found to be associated with a more severe outcome, although the traditional concept in acute liver damage is that irrespective of the etiology, aminotransferase values are not associated with prognosis.
Nevertheless, some studies have found that both fulminant hepatic failure 9, 20 and chronic liver damage 29 in idiosyncratic DILI are associated with high levels of aminotransferases. The present study also points towards the value of AST level, as well as AST/ALT ratio, for prediction of fatal outcome at any time point. These findings are in agreement with previous studies conducted in DILI 9,30 and viral hepatitis patients 31 , and challenge the dogma that the degree of aminotransferase elevation does not have a prognostic value in acute liver injury. Of note, in our cohort AST but not ALT values remained significantly raised in the ALF/OLT group at peak of TBL which occurs at a later phase of liver damage. The AST half-life (mostly cytoplasmic) is shorter (about 8 hours) than that of ALT (about 21 hours). 32 An ongoing increase of the AST component exceeding ALT levels might reflect unrelenting hepatocyte damage, release of mitochondrial AST or possibly some zonal difference in AST versus ALT.
Our initial aim was to attempt improve the definition of Hy's Law in prediction of ALF. Thus, using the nR criteria with the first blood test available after presentation provides a good balance between sensitivity and specificity. The predictive value of AST in our new definition of Hy's Law based on nR criteria may explain the greater sensitivity when compared to the traditional R using ALT. Furthermore, this nR classifies more cases as hepatocellular. However, delayed presentation may diminish M A N U S C R I P T
22 the reliability of predicting ALF risk since there is clearly a tendency for the liver injury pattern to shift to cholestatic/mixed status. This tendency has also been observed previously. 18 Our results do not support the use of absolute ALP level alone in the definition of Hy´s
Law. In our analysis, the percentage of cases with ALP>2 xULN was similar between those with and those without ALF/OLT outcomes, suggesting that an ALP>2 xULN does not predict a lower risk of ALF/OLT. Nevertheless, the ALP elevations seen in the ALF/OLT cases were mostly moderate, with only 2 patients having ALP>4x ULN at DILI recognition. Therefore, we believe it is better to identify Hy´s Law cases as hepatocellular injury (R or nR ≥5) accompanied by hyperbilirubinemia without excluding cases based on the ALP level.
Hy's Law is mainly used as a signal of serious hepatotoxicity during drug development.
Clinical trial settings, where patients undergo sequential liver test monitoring, typically identify cases at an earlier stage of evolution of injury which is dampened by prompt drug withdrawal. Since the nR criteria has been developed in the postmarketing setting and focused on a specific outcome, ALF/OLT, we recommend that the modified Hy´s Law should be tested by regulators especially if they are able to combine large clinical trial datasets to generate sufficient number of ALF events.
Although the modified Hy´s Law performs particularly well in predicting who will not develop ALF (i.e. absence of meeting the nR criteria at DILI recognition) most of the cases who meet the criteria do not develop ALF. Therefore, we extended our analyses beyond the Hy´s Law criteria in an attempt to improve the accuracy for predicting ALF when patients are first seen.
Thus, we developed a prognostic algorithm which may be used by physicians in clinical practice to evaluate DILI cases at recognition regardless of the type of liver
injury. It gives a special weight to the degree of AST elevation and to the AST/ALT ratio, which were found to be independent risk factors for ALF/OLT at all time points in our analysis. Apart from being highly specific while preserving sensitivity, the decision tree also allows the prediction of ALF before total bilirubin values are substantially increased. The choice between using the nR criteria or the prognostic algorithm depends on the physician´s necessity for major sensitivity or specificity in the ALF prognosis.
Thus, the nR criteria will capture most of the ALF cases, while the proposed algorithm 
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Hypersensitivity features included: rash, eosiniphilia, lymphopenia, althralgia, fever and positive autoantibody titres. The percentages shown are calculated based on the total number of episodes with available information. LR: likelihood ratio; TBL: total bilirubin; ALT: alanine aminotransferase; AST: aspartate aminotransferase; ULN: upper limit of normal. *nR calculated with ALT or AST, whichever is highest. 
